Myrbetriq Treatment Guide

What Is Myrbetriq and How Does It Work?

Myrbetriq (mirabegron) is a prescription medication specifically designed to treat overactive bladder symptoms in adults and neurogenic detrusor overactivity in children. Myrbetriq works by activating beta-3 receptors in the bladder muscle, helping it relax and hold more urine.

Overactive bladder affects millions of people and causes three main problems: sudden, strong urges to urinate, leaking urine when you feel the urge, and needing to urinate frequently throughout the day and night. Myrbetriq addresses all three of these symptoms by helping your bladder muscle stay relaxed until it’s time to empty.

Who Can Take Myrbetriq?

Myrbetriq is FDA-approved for two main groups of patients. First, adults with an overactive bladder who experience urge urinary incontinence, urgency, and frequent urination. Second, children aged 3 years and older with neurogenic detrusor overactivity, which is bladder overactivity caused by nervous system problems.

Why Pay Full Price?

Search our full medication catalogue and save up to 80% - no insurance needed.

See Prices Now

This medication fits into a structured treatment approach for an overactive bladder. Most healthcare providers follow a three-step process: lifestyle changes first, then medications like Myrbetriq, and finally minimally invasive procedures if needed. This means your doctor will likely suggest behavioral changes before prescribing Myrbetriq, but the medication can be very effective when lifestyle modifications aren’t enough.

Myrbetriq Dosing Guidelines for Adults

For adults with an overactive bladder, the standard starting dose of Myrbetriq is 25 mg taken once daily. After 4 to 8 weeks, your doctor may increase your dose to 50 mg once daily if you need better symptom control and you’re tolerating the medication well.

Some patients take Myrbetriq in combination with another bladder medication called solifenacin. When used together, the typical starting dose is Myrbetriq 25 mg plus solifenacin 5 mg, both taken once daily. After 4 to 8 weeks, the Myrbetriq portion may be increased to 50 mg while keeping solifenacin at 5 mg.

The extended-release tablets should always be swallowed whole. Never crush, chew, or break them, as this can affect how the medication is absorbed and may cause side effects.

Pediatric Dosing for Neurogenic Detrusor Overactivity

Children with neurogenic detrusor overactivity take Myrbetriq as a liquid suspension rather than tablets. The dosing is based on the child’s weight and starts conservatively. For children weighing 35 kg or more, the starting dose is 6 mL once daily, which can be increased to 10 mL after 4 to 8 weeks if needed.

For children weighing 22-35 kg, the starting dose is 4 mL once daily, with a maximum of 8 mL. Children weighing between 11 and 22 kg start at 3 mL once daily, with careful adjustments based on their tolerance to the medication.

Parents and caregivers must measure the liquid suspension carefully using the measuring device provided with the medication. The dosing is precise, and using household spoons can lead to incorrect doses.

Special Dosing Considerations

Patients with liver problems need adjusted Myrbetriq doses. If you have mild liver impairment (Child-Pugh Class A), you should start with 25 mg and may increase to a maximum of 50 mg. Those with moderate liver impairment (Child-Pugh Class B) should start with 25 mg and stay at that dose without increasing. Myrbetriq is not recommended for people with severe liver impairment.

Kidney function also affects dosing. Patients with severe kidney impairment should not exceed 25 mg daily. Your doctor will check your kidney and liver function before starting Myrbetriq and may monitor these during treatment.

Common Side Effects

Most people tolerate Myrbetriq well, but like all medications, it can cause side effects. The most common side effects reported in clinical trials include high blood pressure, cold-like symptoms (nasopharyngitis), urinary tract infections, upper respiratory tract infections, and headaches.

Many patients find Myrbetriq easier to tolerate than older overactive bladder medications called antimuscarinics. These older drugs often cause dry mouth, constipation, and blurred vision. Myrbetriq works differently and typically causes fewer of these bothersome side effects, leading to better compliance and continued use.

Serious but Rare Side Effects

While uncommon, some serious side effects require immediate medical attention. Angioedema, which is severe swelling of the face, lips, tongue, or throat, has been reported after Myrbetriq use. This is a medical emergency that requires immediate treatment.

Atrial fibrillation, an irregular heart rhythm, has also been reported in some patients. If you experience chest pain, rapid heartbeat, shortness of breath, or dizziness, contact your healthcare provider immediately.

Urinary retention, where you cannot empty your bladder completely, can occur but is rare. This is more likely in patients who already have bladder emptying problems or enlarged prostates.

Blood Pressure Monitoring Requirements

One of the most important aspects of Myrbetriq treatment is regular blood pressure monitoring. The medication can increase blood pressure, so your doctor will check your blood pressure before starting treatment and periodically while you’re taking it.

Myrbetriq is not recommended for people with severe, uncontrolled high blood pressure. If you develop high blood pressure while taking Myrbetriq, your doctor may adjust your blood pressure medications or consider reducing the Myrbetriq dose.

How Effective Is Myrbetriq?

Clinical trials show that Myrbetriq effectively reduces overactive bladder symptoms. In placebo-controlled studies, patients taking Myrbetriq experienced significant reductions in incontinence episodes and the number of times they needed to urinate each day.

The improvements typically become noticeable within the first few weeks of treatment, but maximum benefits may take 8 to 12 weeks to develop. Your healthcare provider may use quality of life questionnaires, such as the OAB-q, to track your progress and determine whether the medication is working effectively for you.

Drug Interactions and Contraindications

Myrbetriq can interact with other medications, so tell your healthcare provider about all prescription drugs, over-the-counter medications, and supplements you’re taking. The medication is metabolized by certain liver enzymes, which means it can affect how other drugs are processed in your body.

The only absolute contraindication to Myrbetriq is a known hypersensitivity or allergy to mirabegron or any of the inactive ingredients in the tablets or suspension. If you’ve had allergic reactions to Myrbetriq in the past, you should not take it again.

What to Expect During Treatment

Starting Myrbetriq treatment involves several steps to ensure safety and effectiveness. Your doctor will review your medical history, current medications, and check your blood pressure and kidney function before prescribing the medication.

During the first few weeks, you should take the medication at the same time each day, preferably with food to reduce the chance of stomach upset. Keep track of your symptoms using a bladder diary, noting how often you urinate, any leakage episodes, and the urgency of your symptoms.

Most patients start noticing improvements within 2 to 4 weeks, but don’t be discouraged if changes are gradual. Your doctor may increase your dose after 4 to 8 weeks if your symptoms haven’t improved sufficiently and you’re tolerating the current dose well.

Long-Term Treatment Considerations

Myrbetriq is designed for long-term use in managing overactive bladder symptoms. Unlike some medications that lose effectiveness over time, Myrbetriq typically maintains its benefits with continued use. However, your healthcare provider will want to see you regularly to monitor your response and check for any side effects.

Periodic blood pressure checks are essential throughout treatment. Your doctor may also reassess your kidney and liver function, especially if you have underlying health conditions or take other medications that could affect these organs.

Some patients may be able to reduce their dose or take medication holidays after their symptoms improve significantly, but this should only be done under medical supervision. Stopping Myrbetriq suddenly won’t cause withdrawal symptoms, but your overactive bladder symptoms will likely return.

Lifestyle Modifications to Enhance Treatment

While Myrbetriq effectively manages overactive bladder symptoms, combining medication with lifestyle changes often provides the best results. Bladder training exercises, such as scheduled urination and gradually increasing the time between bathroom visits, can help retrain your bladder to hold more urine.

Dietary modifications may also help. Limiting caffeine, alcohol, and acidic foods can reduce bladder irritation. Maintaining a healthy weight reduces pressure on the bladder, and pelvic floor exercises strengthen the muscles that control urination.

Staying hydrated is important, but timing your fluid intake can help manage symptoms. Try drinking more fluids earlier in the day and reducing intake a few hours before bedtime to minimize nighttime urination.

When to Contact Your Healthcare Provider

Certain situations require immediate medical attention while taking Myrbetriq. Contact your healthcare provider right away if you experience signs of an allergic reaction, including facial swelling, difficulty breathing, or a severe skin rash.

If you develop chest pain, irregular heartbeat, severe dizziness, or fainting, seek medical care immediately, as these could indicate serious heart rhythm problems. Difficulty urinating or inability to empty your bladder completely also requires prompt evaluation.

For routine concerns, such as questions about effectiveness, mild side effects, or missed doses, contact your healthcare provider’s office during regular hours. They can provide guidance on whether any adjustments to your treatment plan are needed.

References

• Myrbetriq- mirabegron tablet, film coated, extended release; Myrbetriq- mirabegron granule, for suspension, extended release [package insert]. Astellas Pharma US, Inc.  Last updated 4/2021. Accessed July 2, 2026.
• Mirabegron (Myrbetriq) – Drug Information. Medscape. Accessed July 2, 2026.